Pediatric oxycodone dosing



Oxycodone vs Placebo in Children With Undifferentiated Abdominal

12/20/2016
11:39 | Matthew Adderiy
Pediatric oxycodone dosing
Oxycodone vs Placebo in Children With Undifferentiated Abdominal

Research from JAMA Pediatrics — Oxycodone vs Placebo in Children the study medication and at 1 hour and 3.5 hours after initial dosing.

After screening, the children were instructed to use a visual analog scale to score their pain (left end, no pain; right end, worst imaginable pain). 11 The scale was a rectangle 10 cm long and 2 cm tall containing a red triangle that increased in size from left to right. The children expressed the pain score while the research nurse exerted a light pressure on the abdomen.

All 3 surgeons participating in the trial were briefed on the abdominal examination technique. The most important clinical findings suggestive of surgical disease were recorded on a special form ( Table 1 ).

Oxycontin Approved for Pediatric Patients

11/19/2016
10:29 | Hannah Hoggarth
Pediatric oxycodone dosing
Oxycontin Approved for Pediatric Patients

The pediatric patients were initiated on a total daily dose ranging from Oxycontin, an opioid agonist, is now approved for use in pediatric.

For more information call (888) or visit FDA.gov.

The approval is based on a study of 155 pediatric patients previously receiving and tolerating opioids for at least five consecutive days with a minimum of 20mg per day of oxycodone or its equivalent on the two days immediay preceding dosing with Oxycontin. The pediatric patients were initiated on a total daily dose ranging from 20–100mg based on prior opioid dose. The most frequent adverse events observed in pediatric patients were vomiting, nausea, headache, pyrexia, and constipation.

The FDA is requiring postmarketing studies on the serious risks of respiratory depression, accidental injury, overdose, misuse, accidental exposure, and medication errors associated with the use of Oxycontin in opioid-tolerant pediatric patients aged 11–17, and to assess the serious risks of respiratory depression, accidental injury, overdose, misuse, accidental exposure, and medication errors associated with the use of the product in children who are either younger than the approved age range or who do not meet the labeled criteria for opioid tolerance.

Oxycontin Approved for Pediatric Patients

9/17/2016
08:09 | Olivia Holiday
Pediatric oxycodone dosing
Oxycontin Approved for Pediatric Patients

The pediatric patients were initiated on a total daily dose ranging from Oxycontin, an opioid agonist, is now approved for use in pediatric.

For more information call (888) or visit FDA.gov.

RELATED: Do Not Crush or Chew Chart.

The FDA is requiring postmarketing studies on the serious risks of respiratory depression, accidental injury, overdose, misuse, accidental exposure, and medication errors associated with the use of Oxycontin in opioid-tolerant pediatric patients aged 11–17, and to assess the serious risks of respiratory depression, accidental injury, overdose, misuse, accidental exposure, and medication errors associated with the use of the product in children who are either younger than the approved age range or who do not meet the labeled criteria for opioid tolerance.

POSTOPERATIVE PAIN MANAGEMENT

10/18/2016
09:19 | Joshua Addington
Pediatric oxycodone dosing
POSTOPERATIVE PAIN MANAGEMENT

PEDIATRIC POSTOPERATIVE PAIN MANAGEMENT Consider a co-analgesic while on the demand only dose. Oxycodone 0.1 – 0.15 mg/kg po q 4 hours.